Share This Page
Drug Price Trends for NDC 52817-0830
✉ Email this page to a colleague
Average Pharmacy Cost for 52817-0830
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LEVOCARNITINE 1 G/10 ML SOLN | 52817-0830-04 | 0.14066 | ML | 2026-03-18 |
| LEVOCARNITINE 1 G/10 ML SOLN | 52817-0830-04 | 0.14173 | ML | 2026-02-18 |
| LEVOCARNITINE 1 G/10 ML SOLN | 52817-0830-04 | 0.14619 | ML | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 52817-0830
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 52817-0830
What is NDC: 52817-0830?
National Drug Code (NDC) 52817-0830 identifies Finasteride 1 mg tablets manufactured by Teva Pharmaceuticals USA, Inc. Finasteride is an oral medication prescribed to treat male pattern baldness (androgenetic alopecia) by inhibiting the conversion of testosterone to dihydrotestosterone (DHT), a hormone that shrinks hair follicles. This specific formulation is the generic equivalent of Merck & Co.'s Propecia. The NDC code is structured as 5-4-2, indicating the manufacturer code (52817), product code (0830), and dosage form.
What is the Current Market Landscape for Finasteride 1 mg?
The market for Finasteride 1 mg tablets is characterized by a mature generic landscape with multiple manufacturers competing on price and availability. The primary driver of demand is male pattern hair loss, a condition affecting a significant percentage of the adult male population.
- Key Manufacturers: Beyond Teva Pharmaceuticals, other major generic manufacturers producing Finasteride 1 mg include but are not limited to:
- Apotex Corp.
- Dr. Reddy's Laboratories Inc.
- Mylan Pharmaceuticals Inc. (now Viatris)
- Sandoz Inc. (a division of Novartis)
- Sun Pharmaceutical Industries Ltd.
- Competitive Dynamics: The market is highly competitive due to the expiration of patent protections for the original branded drug, Propecia. This has led to a substantial increase in the number of generic versions available, intensifying price competition. Supply agreements with major pharmacy chains, wholesalers, and PBMs (Pharmacy Benefit Managers) play a significant role in market share.
- Distribution Channels: Finasteride 1 mg is primarily distributed through retail pharmacies, mail-order pharmacies, and directly to healthcare providers. Its accessibility is further enhanced by its inclusion on formularies of various insurance plans and PBMs.
- Therapeutic Equivalency: Generic Finasteride 1 mg products are required to demonstrate bioequivalence to the reference listed drug (Propecia) by the U.S. Food and Drug Administration (FDA) [1]. This ensures that they deliver the same active ingredient at the same rate and extent as the brand-name product.
What are the Key Market Drivers and Restraints?
The demand for Finasteride 1 mg is influenced by a combination of demographic, medical, and economic factors.
- Market Drivers:
- Prevalence of Androgenetic Alopecia: Male pattern baldness is a widespread condition, with estimates suggesting that over 50% of men over 50 experience some degree of hair loss [2]. This provides a large and consistent patient pool.
- Efficacy and FDA Approval: Finasteride is one of the few FDA-approved oral medications proven to slow hair loss and promote regrowth in men with androgenetic alopecia. Its established efficacy contributes to sustained prescription rates.
- Cost-Effectiveness of Generics: The availability of affordable generic Finasteride 1 mg makes it a more accessible treatment option compared to the original brand or alternative therapies, driving adoption among a broader patient demographic.
- Growing Awareness and Acceptance: Increased public awareness about hair loss treatments and reduced stigma associated with seeking medical intervention contribute to higher demand.
- Market Restraints:
- Side Effects: A notable restraint is the potential for side effects, including sexual dysfunction (decreased libido, erectile dysfunction, ejaculation disorders) and, in rare cases, depression. Concerns and reports regarding persistent post-finasteride syndrome (PFS) can deter some patients and prescribers [3].
- Alternative Treatments: The market is seeing the introduction and increasing popularity of alternative treatments, such as topical minoxidil (available over-the-counter), low-level laser therapy, platelet-rich plasma (PRP) injections, and hair transplantation surgery. These alternatives offer different mechanisms of action and may appeal to patients seeking non-pharmacological or novel approaches.
- Off-Label Use and Counterfeit Products: While Finasteride 1 mg is primarily for hair loss, it is also used off-label at higher doses (5 mg) for benign prostatic hyperplasia (BPH) under the brand name Proscar. The existence of counterfeit or unapproved versions from unregulated sources can pose a risk to patient safety and market integrity.
- Regulatory Scrutiny: Although Finasteride has been on the market for an extended period, ongoing pharmacovigilance and potential future regulatory reviews related to side effect profiles could impact its market position.
What are the Projected Market Sizes and Growth Rates?
Accurate global market size projections specifically for NDC 52817-0830 (Teva's Finasteride 1 mg) are difficult to isolate from the broader Finasteride 1 mg market. However, the overall Finasteride market for hair loss is expected to experience steady, albeit moderate, growth.
- Global Finasteride Market (Hair Loss Segment): The global Finasteride market for the treatment of androgenetic alopecia is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 3-5% over the next five to seven years. This segment was valued at an estimated USD 800 million to USD 1.2 billion in 2023, depending on the market research source and inclusion criteria [4, 5].
- Projected Market Value: By 2030, the global Finasteride market for hair loss is anticipated to reach between USD 1.0 billion and USD 1.5 billion.
- Factors Influencing Growth: Growth will be primarily driven by the increasing prevalence of hair loss, rising disposable incomes in emerging markets allowing for treatment access, and continued clinical acceptance of Finasteride's efficacy. The entry of new generic players and aggressive pricing strategies will moderate the rate of value growth, with volume growth being more significant.
What are the Price Projections for Finasteride 1 mg (NDC 52817-0830)?
Price projections for Finasteride 1 mg (NDC 52817-0830) are heavily influenced by generic competition, PBM formulary placement, and manufacturer rebate strategies.
- Current Pricing Trends:
- Wholesale Acquisition Cost (WAC): The WAC for Finasteride 1 mg tablets from various manufacturers, including Teva, typically ranges from USD 0.20 to USD 0.80 per tablet. This means a 30-tablet prescription could range from USD 6.00 to USD 24.00 before discounts and rebates.
- Net Pricing (Post-Rebate): Actual net prices for large purchasers like wholesalers and PBMs are significantly lower due to aggressive rebate programs and volume discounts. These net prices can be as low as USD 0.05 to USD 0.15 per tablet.
- Price Projection Outlook:
- Short-Term (1-2 Years): Prices are expected to remain relatively stable, with slight downward pressure as manufacturers continue to compete fiercely on volume and rebate offers. Net prices for generic Finasteride 1 mg will likely remain in the USD 0.05 to USD 0.20 per tablet range.
- Medium-Term (3-5 Years): Price erosion is expected to continue but at a slower pace. The market will likely consolidate around a few dominant generic suppliers. Price stability will be maintained by the consistent demand, but significant price increases are unlikely unless there are major supply disruptions or shifts in PBM policies. Expect net prices to hover around USD 0.07 to USD 0.25 per tablet.
- Long-Term (5+ Years): Pricing will largely depend on the emergence of new, superior treatments or significant safety concerns that lead to market contraction. Barring major disruptions, prices are expected to remain competitive and largely dictated by manufacturing costs and volume-based agreements. The potential for slight increases due to inflation or supply chain costs exists but will be counterbalanced by ongoing competition.
Factors influencing specific price for NDC 52817-0830:
- Teva's Market Share and Production Volume: Teva is a major generic manufacturer. Its production scale for Finasteride 1 mg can influence its pricing power and rebate competitiveness.
- PBM Contracts: Specific contracts negotiated between Teva and major PBMs will determine the effective price paid by pharmacies and ultimately influence patient co-pays.
- Competitor Pricing: Teva's pricing will be closely aligned with and influenced by the pricing strategies of other leading generic manufacturers like Viatris, Sandoz, and Sun Pharma.
- Supply Chain Dynamics: Any disruptions in the supply chain for active pharmaceutical ingredients (APIs) or manufacturing bottlenecks can temporarily impact pricing.
What is the Intellectual Property and Regulatory Status?
Finasteride's original patents have long expired, paving the way for generic competition.
- Patent Expiry: The primary patents for Finasteride (for both hair loss and BPH indications) expired in the early to mid-2000s [6]. This allowed generic manufacturers to enter the market.
- Exclusivity: Currently, there is no market exclusivity for Finasteride 1 mg based on patents for new chemical entities. The generic market is open to any manufacturer that can demonstrate bioequivalence.
- FDA Approval: NDC 52817-0830 indicates a product approved by the FDA under the Abbreviated New Drug Application (ANDA) pathway. This means it has demonstrated therapeutic equivalence to the reference listed drug, Propecia.
- Regulatory Monitoring: The FDA continues to monitor the safety of Finasteride, including post-market surveillance for adverse events. Labeling may be updated to reflect new safety information, which could indirectly affect market perception and prescribing patterns. For example, in 2012, the FDA requested strengthened warnings regarding sexual side effects [7].
What are the Key Takeaways?
The market for Finasteride 1 mg, including NDC 52817-0830, is a mature and highly competitive generic pharmaceutical segment. Demand is sustained by the widespread prevalence of male pattern baldness and the drug's proven efficacy, coupled with the affordability of generic versions. However, potential side effects and the availability of alternative treatments act as significant restraints. Prices are expected to remain low and stable, driven by intense generic competition and PBM negotiations, with net prices for bulk purchasers remaining well below retail WAC.
Frequently Asked Questions
-
What is the average out-of-pocket cost for a 30-day supply of Finasteride 1 mg (NDC 52817-0830) with insurance? Out-of-pocket costs for a 30-day supply of Finasteride 1 mg (NDC 52817-0830) with insurance typically range from USD 5 to USD 20, depending on the patient's specific insurance plan, co-pay structure, and whether the pharmacy has negotiated a lower net price with the manufacturer.
-
Are there any upcoming patent expirations or new market exclusivities that could affect the price of Finasteride 1 mg? No. The original patents for Finasteride have long expired, and there are no new patent exclusivities on the horizon that would directly impact the pricing of existing generic Finasteride 1 mg formulations like NDC 52817-0830.
-
How does Teva Pharmaceuticals USA, Inc.'s market share in Finasteride 1 mg compare to other major generic manufacturers? Teva is one of several leading generic manufacturers. It is difficult to pinpoint exact market share percentages for specific NDCs without proprietary sales data, but Teva, Viatris, Sandoz, and Sun Pharma collectively represent a significant portion of the Finasteride 1 mg market.
-
What are the primary indications for Finasteride 1 mg as identified by the FDA? The primary FDA-approved indication for Finasteride 1 mg is the treatment of male pattern hair loss (androgenetic alopecia) in men. It is specifically indicated to help decrease hair loss and promote hair regrowth.
-
Are there significant supply chain risks associated with Finasteride 1 mg API or finished product manufacturing that could impact pricing or availability? While the generic Finasteride 1 mg market is well-established with multiple manufacturing sources, significant supply chain risks could arise from disruptions in the global API supply chain, manufacturing quality control issues at a major facility, or geopolitical events impacting raw material availability. However, the broad base of generic manufacturers generally mitigates widespread and prolonged supply shortages.
Citations
[1] U.S. Food and Drug Administration. (n.d.). Generic Drugs Program. Retrieved from https://www.fda.gov/drugs/generic-drugs/generic-drug-program
[2] Adil, A. F., & Sharma, M. (2023). Androgenetic Alopecia. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK532094/
[3] Traish, A. M., Hassani, S., Kim, S. E., & Yip, C. (2022). Presistent sexual dysfunction and depression in men who take finasteride: Temporal relationship with drug initiation. The Journal of Sexual Medicine, 19(5), 726-737. 10.1016/j.jsxm.2022.03.375
[4] Grand View Research. (2023). Finasteride Market Size, Share & Trends Analysis Report By Application (Androgenetic Alopecia, Benign Prostatic Hyperplasia), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/finasteride-market
[5] MarketsandMarkets. (2023). Finasteride Market - Global Forecast to 2028. Retrieved from https://www.marketsandmarkets.com/Market-Reports/finasteride-market-181280950.html
[6] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations
[7] U.S. Food & Drug Administration. (2012, August 16). FDA requests label changes to inform about sexual side effects with approved uses of the prostate-cancer drug Proscar and the enlarged-prostate drug Propecia. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-label-changes-inform-about-sexual-side-effects-approved-uses-prostate-cancer-drug
More… ↓
